HuagongsheHuagongshe Chemistry Print Report · For research reference only
2-(1-methoxyethyl)-1H-1,3-benzodiazole → (S)-2-(1-((2-(2-(1-methoxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol
Participants
| Role | Name | HCID | Charge |
|---|---|---|---|
| Reactant | 2-(1-methoxyethyl)-1H-1,3-benzodiazole | HCID 45078472 | — |
| Reactant | 2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol | HCID 59603426 | — |
| Product | (S)-2-(1-((2-(2-(1-methoxyethyl)-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol | HCID 59606137 | 15.9% |
Reaction Steps
2-(1-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperidin-4-yl)propan-2-ol (0.15 g) was reacted with 2-(1-methoxyethyl)-1H-benzo[d]imidazole (97 mg) via General Procedure I for Buchwald coupling to give 32.1 mg of 516 [MS (Q1) 549.4 (M)+] and 32.4 mg of 519 [MS (Q1) 549.3 (M)+] following reverse phase purification and subsequent chiral separation.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| Patent number | US08173650B2 |
| Source dataset | uspto-grants-2012_05 |
| ORD ID | ord-cb13eb666a49418e856b16376c6a8da4 |
| Source note | uspto-grants-2012_05 |